利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

59 条记录 (耗时 0.06 秒)

    Methods and materials for assessing prostate cancer therapies and compounds
    2.
    发明申请
    Methods and materials for assessing prostate cancer therapies and compounds 有权
    用于评估前列腺癌疗法和化合物的方法和材料

    公开(公告)号：US20070191443A1

    公开(公告)日：2007-08-16

    申请号：US10590445

    申请日：2005-02-23

    申请人： Michael Jung ,  Samedy Ouk ,  Charles Sawyers ,  Charlie Chen ,  Derek Welsbie

    发明人： Michael Jung ,  Samedy Ouk ,  Charles Sawyers ,  Charlie Chen ,  Derek Welsbie

    IPC分类号： A61K31/4166 ,  C07D233/84

    CPC分类号： A61K31/426

    摘要： A modest (2-5 fold) increase in androgen receptor (AR) mRNA is the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides for the design of novel antiandrogen compounds.

    摘要翻译： 雄激素受体（AR）mRNA的适度（2-5倍）增加是与抗雄激素治疗发展抵抗力的唯一表达变化。 增加的AR水平通过放大来自低水平的残留配体的信号输出并改变对拮抗剂的正常反应来赋予抗雄激素抗性。 本发明提供用于检查新的治疗方式的基于细胞的测定法，并提供新的抗雄激素化合物的设计。

    METHODS AND MATERIALS FOR ASSESSING PROSTATE CANCER THERAPIES AND COMPOUNDS
    3.
    发明申请
    METHODS AND MATERIALS FOR ASSESSING PROSTATE CANCER THERAPIES AND COMPOUNDS 有权
    用于评估前列腺癌治疗和化合物的方法和材料

    公开(公告)号：US20080090888A2

    公开(公告)日：2008-04-17

    申请号：US10590445

    申请日：2006-08-24

    申请人： Michael Jung ,  Samedy Ouk ,  Charles Sawyers ,  Charlie Chen ,  Derek Welsbie

    发明人： Michael Jung ,  Samedy Ouk ,  Charles Sawyers ,  Charlie Chen ,  Derek Welsbie

    IPC分类号： A61K31/4166 ,  C07D233/84

    CPC分类号： A61K31/426

    摘要： A modest (2-5 fold) increase in androgen receptor (AR) mRNA is the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides for the design of novel antiandrogen compounds.

    摘要翻译： 雄激素受体（AR）mRNA的适度（2-5倍）增加是与抗雄激素治疗发展抵抗力的唯一表达变化。 增加的AR水平通过放大来自低水平的残留配体的信号输出并改变对拮抗剂的正常反应来赋予抗雄激素抗性。 本发明提供用于检查新的治疗方式的基于细胞的测定法，并提供新的抗雄激素化合物的设计。

    Methods and materials for assessing prostate cancer therapies
    4.
    发明申请
    Methods and materials for assessing prostate cancer therapies 有权
    用于评估前列腺癌疗法的方法和材料

    公开(公告)号：US20070166717A1

    公开(公告)日：2007-07-19

    申请号：US10583280

    申请日：2004-12-16

    申请人： Charles Sawyer ,  Charlie Chen ,  Derek Welsbie

    发明人： Charles Sawyer ,  Charlie Chen ,  Derek Welsbie

    IPC分类号： C12Q1/68 ,  A61K48/00

    CPC分类号： G01N33/57434 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/5011 ,  G01N2333/723 ,  G01N2500/04

    摘要： Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest (2-5 fold) increase in androgen receptor (AR) mRNA was the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides insight toward the design of novel antiandrogens.

    摘要翻译： 使用基于芯片的同基因前列腺癌异种移植模型，我们发现雄激素受体（AR）mRNA的适度（2-5倍）增加是与抗雄激素治疗发展抵抗力的唯一表达变化。 增加的AR水平通过放大来自低水平的残留配体的信号输出并改变对拮抗剂的正常反应来赋予抗雄激素抗性。 本发明提供用于检查新治疗方式的基于细胞的测定法，并提供对新型抗雄激素的设计的洞察。

    Molecular Signature of the Pten Tumor Suppressor
    5.
    发明申请
    Molecular Signature of the Pten Tumor Suppressor 审中-公开
    Pten肿瘤抑制因子的分子标记

    公开(公告)号：US20070253953A1

    公开(公告)日：2007-11-01

    申请号：US10582841

    申请日：2004-12-15

    申请人： Charlie Chen ,  Charles Sawyers

    发明人： Charlie Chen ,  Charles Sawyers

    IPC分类号： A61K39/395 ,  C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136

    摘要： The present invention relates to the identification a molecular signature for PTEN tumor suppressor. The molecular signature comprising a gene or genes that are of use for diagnosis, prognosis, drug research and development and therapeutics. Specifically, the present invention relates to identification of IGFBP2 gene, its mRNA and/or protein products that closely associate with PTEN mutations. The present invention further demonstrates that IGFBP2 expression is negatively regulated by PTEN, positively regulated by PI3K and Akt activation, that IGFBP2 plays a functional role in the PTEN signaling and is required for Akt transformation. The use of IGFBP2 gene, its gene product such as its RNA transcript, protein and molecular probes in diagnosis, prognosis, drug discovery and validation and therapeutic target and therapeutics is also contemplated.

    摘要翻译： 本发明涉及鉴定PTEN肿瘤抑制因子的分子特征。 该分子标记包括用于诊断，预后，药物研究和开发以及治疗用途的基因或基因。 具体地说，本发明涉及与PTEN突变密切相关的IGFBP2基因，其mRNA和/或蛋白质产物的鉴定。 本发明进一步证明IGFBP2表达受PTEN负调节，由PI3K和Akt活化正调节，IGFBP2在PTEN信号中起着功能作用，是Akt转化所必需的。 还考虑使用IGFBP2基因，其基因产物如其RNA转录物，蛋白质和分子探针在诊断，预后，药物发现和验证以及治疗靶标和治疗剂中。

    Wettable Silicone Hydrogel Contact Lenses
    7.
    发明申请
    Wettable Silicone Hydrogel Contact Lenses 有权
    可湿性硅胶水凝胶隐形眼镜

    公开(公告)号：US20140022506A1

    公开(公告)日：2014-01-23

    申请号：US13983577

    申请日：2012-02-23

    申请人： Ye Hong ,  Li Yao ,  Yuwen Liu ,  Charlie Chen ,  Arthur Back

    发明人： Ye Hong ,  Li Yao ,  Yuwen Liu ,  Charlie Chen ,  Arthur Back

    IPC分类号： G02C7/04

    CPC分类号： G02C7/049 ,  C08L83/12 ,  G02B1/043 ,  C08L101/14 ,  C08L83/04 ,  C08L51/085

    摘要： Silicone hydrogel contact lenses are formed from the reaction product of a polymerizable composition comprising at least one acrylate-containing siloxane monomer, at least one hydrophilic vinyl-containing monomer, and at least one vinyl-containing cross-linking agent, wherein the polymerizable composition has a molar ratio of total amount of hydrophilic vinyl-containing monomer to total amount of acrylate-containing siloxane monomer of from 5:1 to 30:1, respectively. The silicone hydrogel contact lenses have good manufacturing processability, can be manufactured without the use of alcohol solvents, and have excellent surface wettability.

    摘要翻译： 硅氧烷水凝胶隐形眼镜由包含至少一种含丙烯酸酯的硅氧烷单体，至少一种亲水性含乙烯基单体和至少一种含乙烯基交联剂的可聚合组合物的反应产物形成，其中可聚合组合物具有 亲水性含乙烯基单体的总量与含丙烯酸酯的硅氧烷单体的总量的摩尔比分别为5:1至30:1。 硅酮水凝胶隐形眼镜具有良好的制造加工性，可以在不使用醇溶剂的情况下制造，并且具有优异的表面润湿性。

    Silicone hydrogel contact lenses having acceptable levels of energy loss
    9.
    发明授权
    Silicone hydrogel contact lenses having acceptable levels of energy loss 有权
    硅酮水凝胶隐形眼镜具有可接受的能量损失水平

    公开(公告)号：US08481662B2

    公开(公告)日：2013-07-09

    申请号：US13404040

    申请日：2012-02-24

    申请人： Ronghua Liu ,  Xinfeng Shi ,  Yuwen Liu ,  Charlie Chen ,  Ye Hong ,  Charles A. Francis ,  Li Yao ,  Arthur Back ,  Ying Zheng

    发明人： Ronghua Liu ,  Xinfeng Shi ,  Yuwen Liu ,  Charlie Chen ,  Ye Hong ,  Charles A. Francis ,  Li Yao ,  Arthur Back ,  Ying Zheng

    IPC分类号： C08F230/08 ,  C08F290/06 ,  G02B1/04

    CPC分类号： G02C7/04 ,  G02B1/043 ,  C08L83/04 ,  C08L101/14

    摘要： Silicone hydrogel contact lenses having ophthalmically acceptable levels of energy loss are described. The lenses are derived from a polymerizable composition including a first siloxane monomer represented by formula (1): wherein m of formula (1) represents one integer from 3 to 10, n of formula (1) represents one integer from 1 to 10, R1 of formula (1) is an alkyl group having from 1 to 4 carbon atoms, and each R2 of formula (1) is independently either a hydrogen atom or a methyl group; the lenses also include units derived from a second siloxane monomer which is a dual-end methacrylate end-capped polydimethylsiloxane having a number average molecular weight of at least 7,000 daltons. Batches of silicone hydrogel contact lenses and methods of making silicone hydrogel contact lenses are also described.

    摘要翻译： 描述了具有眼睛上可接受的能量损失水平的硅酮水凝胶隐形眼镜。 透镜衍生自包含由式（1）表示的第一硅氧烷单体的可聚合组合物：其中式（1）的m表示3至10的一个整数，式（1）的n表示1至10的整数，R 1 式（1）的烷基是碳原子数为1〜4的烷基，式（1）的各R 2独立地为氢原子或甲基。 透镜还包括衍生自第二硅氧烷单体的单元，其是数均分子量至少为7,000道尔顿的双末端甲基丙烯酸酯封端的聚二甲基硅氧烷。 还描述了硅胶水凝胶隐形眼镜的批次和制造硅酮水凝胶隐形眼镜的方法。

    Wettable hydrogel materials for use in ophthalmic applications and methods
    10.
    发明授权
    Wettable hydrogel materials for use in ophthalmic applications and methods 有权
    用于眼科应用和方法的可湿性水凝胶材料

    公开(公告)号：US08410190B2

    公开(公告)日：2013-04-02

    申请号：US13146414

    申请日：2010-09-21

    申请人： Peter Zhu ,  Ying Ye ,  Yun Zhang ,  Charlie Chen

    发明人： Peter Zhu ,  Ying Ye ,  Yun Zhang ,  Charlie Chen

    IPC分类号： G02B1/04

    CPC分类号： C08J7/16

    摘要： A contact lens is provided that has extended and rechargeable wettability. The contact lens includes a lens body that is a reaction product of a polymerizable composition. A first polyhydric alcohol having a 1,2 diol or 1,3 diol moiety is present on a lens surface of the lens body. A contact lens package including the contact lens, and methods of producing and using the contact lens, are also provided.

    摘要翻译： 提供了一种具有延长和充分润湿性的隐形眼镜。 隐形眼镜包括作为可聚合组合物的反应产物的透镜体。 具有1,2-二醇或1,3-二醇部分的第一多元醇存在于透镜体的透镜表面上。 还提供了包括隐形眼镜的隐形眼镜包，以及制造和使用隐形眼镜的方法。